請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20948
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 歐大諒 | |
dc.contributor.author | Yi-Chieh Yang | en |
dc.contributor.author | 楊奕婕 | zh_TW |
dc.date.accessioned | 2021-06-08T03:11:54Z | - |
dc.date.copyright | 2017-09-08 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-03-16 | |
dc.identifier.citation | 1. Warburg O. On the origin of cancer cells. Science. 1956;123:309-14.
2. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends in biochemical sciences. 1999;24:68-72. 3. Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, Sanchez-Garcia FJ. Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance. Frontiers in immunology. 2016;7:52. 4. Hunt TK, Aslam RS, Beckert S, Wagner S, Ghani QP, Hussain MZ, et al. Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxidants & redox signaling. 2007;9:1115-24. 5. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812-9. 6. Nagarajan A, Malvi P, Wajapeyee N. Oncogene-directed alterations in cancer cell metabolism. Trends in cancer. 2016;2:365-77. 7. Maya-Mendoza A, Ostrakova J, Kosar M, Hall A, Duskova P, Mistrik M, et al. Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress. Molecular oncology. 2015;9:601-16. 8. Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:8983-8. 9. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762-5. 10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-33. 11. Lincet H, Icard P. How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions? Oncogene. 2015;34:3751-9. 12. Yu-Chan Chang Y-HJ, Chia-Yi Su, Michael Hsiao. Non-glycolytic Function of Aldolase A Promotes Lung Cancer Metastasis through Down-regulation of PLD2 Enzyme to Activate PLD1. The FASEB Journal. 2015;29. 13. Ritterson Lew C, Tolan DR. Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism. The Journal of biological chemistry. 2012;287:42554-63. 14. Satou W, Tanimoto H, Ukekawa R, Fujii M, Ayusawa D. Amplification of nuclear aldolase A in mouse cell mutants resistant to Hoechst 33342. Biochemical and biophysical research communications. 2004;315:845-9. 15. Watanabe H, Takehana K, Date M, Shinozaki T, Raz A. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer research. 1996;56:2960-3. 16. Tsutsumi S, Hogan V, Nabi IR, Raz A. Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer research. 2003;63:242-9. 17. Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. International journal of cancer. 2003;107:707-14. 18. Colell A, Green DR, Ricci JE. Novel roles for GAPDH in cell death and carcinogenesis. Cell death and differentiation. 2009;16:1573-81. 19. Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer research. 2003;63:100-6. 20. Nicholls C, Pinto AR, Li H, Li L, Wang L, Simpson R, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces cancer cell senescence by interacting with telomerase RNA component. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:13308-13. 21. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. The international journal of biochemistry & cell biology. 2011;43:969-80. 22. Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. The Journal of biological chemistry. 1987;262:14366-71. 23. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230-3. 24. Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;18:5554-61. 25. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry. 2005;44:9417-29. 26. Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 2012;491:458-62. 27. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2:ra73. 28. Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, et al. Mitogenic and Oncogenic Stimulation of K433 Acetylation Promotes PKM2 Protein Kinase Activity and Nuclear Localization. Molecular cell. 2013;52:1-13. 29. Parnell KM, Foulks JM, Nix RN, Clifford A, Bullough J, Luo B, et al. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Molecular cancer therapeutics. 2013;12:1453-60. 30. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8:839-47. 31. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-39. 32. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-500. 33. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:13306-11. 34. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature reviews Cancer. 2005;5:341-54. 35. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57. 36. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-67. 37. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17:1169-80. 38. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73. 39. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786-92. 40. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145:732-44. 41. Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Molecular cell. 2012;45:598-609. 42. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011;480:118-22. 43. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012;150:685-96. 44. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol. 2012;14:1295-304. 45. Yuan S, Yu SL, Chen HY, Hsu YC, Su KY, Chen HW, et al. Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. J Clin Oncol. 2011;29:3435-42. 46. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature reviews Cancer. 2010;10:760-74. 47. Vollmer SH, Walner MB, Tarbell KV, Colman RF. Guanosine 5'-O-[S-(4-bromo-2,3-dioxobutyl)]thiophosphate and adenosine 5'-O-[S-(4-bromo-2,3-dioxobutyl)]thiophosphate. New nucleotide affinity labels which react with rabbit muscle pyruvate kinase. The Journal of biological chemistry. 1994;269:8082-90. 48. Le Mellay V, Houben R, Troppmair J, Hagemann C, Mazurek S, Frey U, et al. Regulation of glycolysis by Raf protein serine/threonine kinases. Adv Enzyme Regul. 2002;42:317-32. 49. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452:181-6. 50. Chung BM, Dimri M, George M, Reddi AL, Chen G, Band V, et al. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene. 2009;28:1821-32. 51. Wang P, Sun C, Zhu T, Xu Y. Structural insight into mechanisms for dynamic regulation of PKM2. Protein & cell. 2015;6:275-87. 52. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer research. 2005;65:6401-8. 53. Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB, et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer research. 2006;66:6990-7. 54. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nature reviews Molecular cell biology. 2010;11:515-28. 55. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-74. 56. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nature reviews Cancer. 2006;6:876-85. 57. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer research. 2006;66:11389-98. 58. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer research. 2010;70:8822-31. 59. Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH, et al. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol. 2012;18:4037-43. 60. Li J, Yang Z, Zou Q, Yuan Y, Li J, Liang L, et al. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer. Clin Transl Oncol. 2014;16:200-7. 61. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, et al. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Molecular cell. 2014;53:75-87. 62. Keller KE, Doctor ZM, Dwyer ZW, Lee YS. SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. Molecular cell. 2014;53:700-9. 63. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 2013;155:397-409. 64. Cortes-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, et al. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:489-94. 65. Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, et al. EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. Molecular cell. 2012;48:771-84. 66. Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, et al. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer research. 2016;76:1284-96. 67. Yang YC, Cheng TY, Huang SM, Su CY, Yang PW, Lee JM, et al. Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association. Oncogene. 2016;35:3387-98. 68. Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer discovery. 2013;3:1404-15. 69. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3342-50. 70. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer discovery. 2014;4:1046-61. 71. Haspinger ER, Garassino MC, Torri V, Cinquini M, De Braud F, Gelsomino F. Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations? J Clin Oncol. 2014;32:859-63. 72. Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell reports. 2014;7:999-1008. 73. Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer. 2012;75:161-6. 74. Chiosis G, Dickey CA, Johnson JL. A global view of Hsp90 functions. Nature structural & molecular biology. 2013;20:1-4. 75. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13:1775-82. 76. Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med. 2012;209:217-24. 77. Liu 劉H-Y. 探討核內M2型丙酮酸激酶誘導癌細胞復育以抵抗葡萄糖缺乏逆境 (Nuclear pyruvate kinase M2 induces tumor repopulaiton to strive against glucose delpetion stress): National Taiwan University; 2015. 78. Novotny I, Dite P, Dastych M, Zakova A, Trna J, Novotna H, et al. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer. Hepatogastroenterology. 2008;55:1475-7. 79. Hamabe A, Konno M, Tanuma N, Shima H, Tsunekuni K, Kawamoto K, et al. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:15526-31. 80. Keller KE, Tan IS, Lee YS. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science. 2012;338:1069-72. 81. Koren E, Fuchs Y. The bad seed: Cancer stem cells in tumor development and resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2016;28:1-12. 82. Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. Journal of hematology & oncology. 2016;9:74. 83. Lane SW, Williams DA, Watt FM. Modulating the stem cell niche for tissue regeneration. Nature biotechnology. 2014;32:795-803. 84. Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell stem cell. 2015;16:225-38. 85. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. British journal of cancer. 2010;102:789-95. 86. Peng G, Liu Y. Hypoxia-inducible factors in cancer stem cells and inflammation. Trends in pharmacological sciences. 2015;36:374-83. 87. Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nature neuroscience. 2013;16:1373-82. 88. Pasto A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi M, Guzzo G, et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 2014;5:4305-19. 89. Liu PP, Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL, et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell death and differentiation. 2014;21:124-35. 90. Wang YH, Israelsen WJ, Lee D, Yu VW, Jeanson NT, Clish CB, et al. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell. 2014;158:1309-23. 91. Grainger SJ, Serna JV, Sunny S, Zhou Y, Deng CX, El-Sayed ME. Pulsed ultrasound enhances nanoparticle penetration into breast cancer spheroids. Molecular pharmaceutics. 2010;7:2006-19. 92. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129:465-72. 93. Kunz M, Ibrahim SM. Molecular responses to hypoxia in tumor cells. Molecular cancer. 2003;2:23. 94. Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell. 2013;153:1064-79. 95. Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine. 2012;7:597-615. 96. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-15. 97. Wu S, Yin X, Fang X, Zheng J, Li L, Liu X, et al. c-MYC responds to glucose deprivation in a cell-type-dependent manner. Cell death discovery. 2015;1:15057. 98. Kodiha M, Rassi JG, Brown CM, Stochaj U. Localization of AMP kinase is regulated by stress, cell density, and signaling through the MEK-->ERK1/2 pathway. American journal of physiology Cell physiology. 2007;293:C1427-36. 99. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature reviews Molecular cell biology. 2012;13:251-62. 100. Carling D, Sanders MJ, Woods A. The regulation of AMP-activated protein kinase by upstream kinases. International journal of obesity. 2008;32 Suppl 4:S55-9. 101. Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase. Molecular and cellular biology. 2007;27:4317-27. 102. Kazgan N, Williams T, Forsberg LJ, Brenman JE. Identification of a nuclear export signal in the catalytic subunit of AMP-activated protein kinase. Molecular biology of the cell. 2010;21:3433-42. 103. Lee J, Kim HK, Han YM, Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. The international journal of biochemistry & cell biology. 2008;40:1043-54. 104. Kellner S, Kikyo N. Transcriptional regulation of the Oct4 gene, a master gene for pluripotency. Histology and histopathology. 2010;25:405-12. 105. Wang X, Zhu Y, Ma Y, Wang J, Zhang F, Xia Q, et al. The role of cancer stem cells in cancer metastasis: new perspective and progress. Cancer epidemiology. 2013;37:60-3. 106. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? British journal of cancer. 2009;100:865-9. 107. Jeon SM, Hay N. The dark face of AMPK as an essential tumor promoter. Cellular logistics. 2012;2:197-202. 108. Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M, et al. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene. 2002;21:6082-90. 109. Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De Lay M, et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Molecular cell. 2010;37:620-32. 110. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Molecular cancer therapeutics. 2009;8:733-41. 111. Kowall B, Stang A, Rathmann W, Kostev K. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiology and drug safety. 2015;24:865-74. 112. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes care. 2014;37:2522-32. 113. Zhang X, He C, He C, Chen B, Liu Y, Kong M, et al. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathology, research and practice. 2013;209:510-5. 114. Morfouace M, Lalier L, Oliver L, Cheray M, Pecqueur C, Cartron PF, et al. Control of glioma cell death and differentiation by PKM2-Oct4 interaction. Cell death & disease. 2014;5:e1036. 115. Liang J, Cao R, Zhang Y, Xia Y, Zheng Y, Li X, et al. PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. Nature communications. 2016;7:12431. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20948 | - |
dc.description.abstract | 代謝途徑的變異是癌細胞的重要指標之一,目前已知癌細胞並不需仰賴週遭氧氣濃度即產生有氧糖解作用 (aerobic glycolysis) 生成能量和大量乳酸 (lactate),又稱瓦伯格效應 (Warburg effect)。PKM2 (Pyruvate kinase M2;M2型丙酮酸激酶) 已知為糖解作用中重要的速率決定步驟之關鍵酵素,癌細胞可透過多種訊息傳遞途徑進而調控其酵素活性,已被證實在調控癌細胞之代謝變異中扮演重要的角色。然而,除了已知的醣代謝酵素活性調控之外,近年來許多文獻指出M2型丙酮酸激酶 (PKM2) 具有多種細胞核內非代謝功能 (nonmetabolic function),可做為一蛋白激酶 (protein kinase) 接受細胞生長訊息以磷酸化下游蛋白,促使癌細胞分裂並且抵抗環境壓力。
表皮細胞生長因子受器 (EGFR) 突變常被發現於非小細胞肺癌中,並開啟致癌的訊息傳遞路徑。表皮細胞生長因子受器酪胺酸激脢的抑制劑 (EGFR-TKI)已用於病人治療多年,但長期使用後常會造成抗藥性;開發抵抗藥物抗藥性的新方式是迫切必須的。本研究的第一部分,發現了細胞質中M2型丙酮酸激酶 (PKM2) 新穎的非代謝功能。在細胞質中,M2型丙酮酸激酶 (PKM2) 可作為一佐監護蛋白 (cochaperone) 透過與熱休克蛋白90 (heat shock protein 90; HSP90) 共同作用,以達到穩定表皮細胞生長因子受器 (EGFR) 的表現量;研究中也發現,細胞中主要是透過低酵素活性的二聚體 (dimeric) PKM2來達到穩定EGFR的表現,若給予細胞活化劑使PKM2成為四聚體 (tetramer),則會減短 EGFR蛋白的酵素半衰期,穩定效果大幅降低。在突變病人中也觀察到PKM2與EGFR表現量呈正相關,並且PKM2高表現會與造成較差病人的無疾病存活期 (disease free survival)。本研究發現了PKM2在細胞質中非代謝酵素的功能,同時也提供了對抗EGFR-TKI抗藥性的新策略。 另一方面,腫瘤的長大的過程中因為血管生成的缺乏,使得中心癌細胞處於缺乏葡萄糖 (glucose) 的環境,對於此環境造成的代謝壓力,癌細胞需要有其適應方式才能繼續存活。在本研究的第二部分,我們發現葡萄糖缺乏會促使細胞質中的PKM2 進入細胞核,增加癌幹細胞族群以對抗代謝壓力。當細胞缺乏葡萄糖時,會活化腺苷單磷酸活化蛋白激酶 (AMP-activated protein kinase; AMPK),透過 Ran (Ras-related nuclear protein) 將PKM2同時帶入細胞核中。細胞核中大量累積的PKM2蛋白會進一步與八聚體結合轉錄因4 (octamer-binding transcription factor 4; OCT4) 共同活化下游與癌幹細胞相關的基因表現。除此之外,動物實驗結果指出核內PKM2可促進癌細胞的轉移能力。本部分研究指出細胞質中的AMPK會協同PKM2進入細胞核以增加癌幹細胞族群,並進一步幫助癌細胞對抗葡萄糖缺乏誘發之代謝壓力。 有別於過去已知PKM2在細胞質中糖解作用的代謝酵素角色,本研究在不同細胞模式提供PKM2細胞質與細胞核中新穎之非代謝功能。透過了解此多樣的機制,能夠提供針對PKM2設計的抗癌藥物更全方面的思考。 | zh_TW |
dc.description.abstract | Metabolic alteration is one of the hallmarks of cancer cells. In contrast to normal cells, cancer cells had been reported to highly rely on aerobic glycolysis even the oxygen concentration is sufficient. This phenomenon is also called “Warburg effect”. Pyruvate kinase isoenzyme M2 (PKM2) is one of the rate-limiting enzymes in the glycolysis process, which catalyzes PEP into ATP and pyruvate. In addition to the well-established metabolic function, PKM2 works as a protein kinase in cancer cells were revealed in the past years. Both metabolic and nonmetabolic functions of PKM2 provide the advantage for the growth of cancer cells.
The secondary mutation of EGFR resulted in drug resistance is one of the most critical issues in lung cancer therapy. In the first part of this study, we report that PKM2 stabilizes mutant EGFR protein and sustain cell survival signaling in lung cancer cells. The depletion of PKM2 leads to proteasome degradation of EGFR and significantly inhibited the tumor growth of EGFR mutant cells in xenograft model. Mechanistically, PKM2 directly interacts with mutant EGFR and stabilize EGFR by maintaining its binding with HSP90 and co-chaperones. Stabilization of EGFR is relied on dimeric PKM2, and the protein half-life of mutant EGFR was decreased when PKM2 was forced to form tetramer after treating activators. Clinical levels of PKM2 positively correlate with mutant EGFR expression and correlate with patient outcome. Most of solid tumors suffer from glucose limited since the less amounts of vessels into tumor core. In the second part of the study, we found the nuclear translocation of the glycolic key enzyme, PKM2, in response to glucose deprivation in cancer cells. We demonstrate that glucose deprivation stimulates the AMPK activation and results in the nuclear translocation of PKM2 through Ran protein. Nuclear PKM2 then binds with OCT4 to promote the expression of cancer stemness-related genes. Thus, the nuclear PKM2 is able to enrich the cancer stem cell population. Furthermore, the nuclear PKM2 promotes cancer metastasis in an orthotopic xenograft model. Our findings provide first evidence that the cytosolic nutrient sensor AMPK works as a cooperator to help PKM2 carry out its nonmetabolic function in nucleus, and that is necessary for repopulation of cancer cells against and adapt to the metabolic stress. These results reveal a previously undescribed non-glycolysis function of PKM2 in cytoplasm and nucleus, and that provide a novel insight for the scientists to develop the drugs which target on PKM2. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T03:11:54Z (GMT). No. of bitstreams: 1 ntu-106-D00453001-1.pdf: 5613632 bytes, checksum: 4d9d7be8eddd71d4292a0ccd100d4841 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員審定書 (I)
中文摘要 (II) Abstract (IV) Background and overview (1) Part 1: Cytosolic PKM2 in maintaining EGFR protein stability through regulating HSP90 pathway (8) A. Introduction (9) B. Purpose (11) C. Materials and methods (12) D. Results (18) E. Discussion (29) Part 2: Nuclear PKM2 promotes cancer stem cell enrichment under glucose deprivation (36) A. Introduction (37) B. Purpose (40) C. Materials and methods (41) D. Results (47) E. Discussion (55) Conclusions (59) References (60) Tables (70) Figures (74) Appendix (117) | |
dc.language.iso | en | |
dc.title | 探討丙酮酸激酶M2之非代謝酵素功能在肺癌及胰臟癌進成中所扮演的角色 | zh_TW |
dc.title | Non-metabolic Function of PKM2 in the Progression of Lung Cancer and Pancreatic Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 華國泰 | |
dc.contributor.oralexamcommittee | 鄭安理,蕭宏昇,李明學 | |
dc.subject.keyword | 表皮細胞生長因子受器,丙酮酸激?M2,表皮細胞生長因子受器酪胺酸激?的抑制劑,癌幹細胞,腺?單磷酸活化蛋白激?,葡萄糖缺乏, | zh_TW |
dc.subject.keyword | EGFR,PKM2,EGFR TKIs,glucose deprivation,cancer stem cell,AMPK, | en |
dc.relation.page | 121 | |
dc.identifier.doi | 10.6342/NTU201700692 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2017-03-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 腫瘤醫學研究所 | zh_TW |
顯示於系所單位: | 腫瘤醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 5.48 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。